BioReliance
BioReliance is a contract testing services brand within MilliporeSigma (Merck KGaA) that provides biosafety, analytical, and viral clearance testing for biomanufacturers developing biologics, mAbs, mRNA, and cell and gene therapies across global facilities.
- Company typePrivate
- Founded1948
- HeadquartersRockville, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
BioReliance firmographics
Firmographics- Name
- BioReliance
- Legal name
- BioReliance (brand of MilliporeSigma, part of Merck KGaA)
- Website
- https://bioreliance.com
- Company type
- Private
- Founded year
- 1948
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- BioReliance is a contract testing services brand within MilliporeSigma (Merck KGaA) that provides biosafety, analytical, and viral clearance testing for biomanufacturers developing biologics, mAbs, mRNA, and cell and gene therapies across global facilities.
- Ownership category
- akta.pro rank
BioReliance industry classification
Industry- Product category
- Biopharmaceutical Contract Testing Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)
- akta.pro secondary industries
- Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), Laboratory Quality & GLP/GCLP Compliance (HLAGAKAK)
Keywords
Where BioReliance is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
BioReliance business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Contract Testing Services: BioReliance provides comprehensive contract testing services for biomanufacturers including analytical development, biosafety testing, viral clearance studies, cell and viral bank testing, raw materials testing, and drug substance/product release testing. Revenue is generated through project-based contracts with pharmaceutical and biotech companies across preclinical through commercial phases.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
BioReliance product offering
Product offeringCore offering
BioReliance provides contract testing services for biopharmaceutical and biotechnology manufacturers, spanning analytical development, biosafety testing, viral clearance studies, cell and viral bank testing, raw materials testing, and drug substance/product release testing from pre-clinical through licensed production. Services leverage proprietary platforms including the Blazar® molecular detection system and GMP-compliant Next Generation Sequencing (NGS), and are delivered through global facilities in Rockville, Glasgow, Stirling, and Singapore.
Product overview
BioReliance® Contract Testing Services is a comprehensive biosafety testing and analytical development platform offering end-to-end contract testing services for biopharmaceutical manufacturers. The portfolio centers on the BioReliance® Contract Testing brand and includes specialized technology platforms (Blazar® Platform for targeted molecular detection, Next Generation Sequencing services), service offerings (Analytical Development, Viral Clearance Testing via Provise® Clearance Service, Cell and Viral Bank Testing, Raw Material Testing, Bulk Harvest Release Testing, Drug Product Release Testing), and client portals (iNet Portal, Synetra™). The services support all phases from preclinical through commercial production, with facilities in Glasgow, Stirling, Singapore, and Rockville.
Differentiator
Problem solved
Functional benefit
Brands
- Blazar® Platform: Targeted molecular technology platform that combines advanced multiplexing with degenerate PCR to rapidly detect adventitious viruses from multiple virus families
- Provise® Clearance Service
- Synetra™
Products and services
- BioReliance® Contract Testing Services
- Analytical Development and Product Characterization
- Blazar® Platform
- Provise® Clearance Service
- Viral Clearance Testing Services
- Next Generation Sequencing (NGS) Services
- Cell and Viral Bank Testing
- Raw Material Testing
- Bulk Harvest Release Testing
- Drug Product Release Testing
- iNet Portal
- Synetra™ Client Portal
Quantifiable outcome
- 17,300+ viral clearance studies completed in U.S., UK, and Singapore facilities
- +1 more outcomes
Companies that use BioReliance
Customer profileSegments1 record
Ideal customer profiles1 record
BioReliance technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
BioReliance partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights5 records
BioReliance competitors and assessment
Company assessmentBroad incumbents
- Eurofins Scientific: Largest global testing services group offering pharmaceutical and biopharma product testing, including biosafety and analytical services, competing with BioReliance across multiple geographies.
- Lonza Group: Major CDMO with in-house and contract biosafety testing, viral clearance, and cell banking services as part of its integrated biologics offering, overlapping BioReliance's testing services.
- Catalent: Global CDMO providing biologics development and testing services, including analytical and release testing for cell and gene therapies, overlapping BioReliance's biomanufacturer testing portfolio.
- Sartorius: Bioprocessing and testing solutions provider with overlapping analytical and quality testing capabilities for biomanufacturers, particularly through its lab products and services division.
Direct peers
- WuXi AppTec (WuXi Biologics): Major Asia-based CRO/CDMO providing biosafety testing, viral clearance, and cell line characterization for biologics, directly competing with BioReliance especially in mAb and gene therapy testing.
- Intertek Pharmaceutical Services: Provides biosafety, viral clearance, and GMP testing for biologics manufacturers, with labs in the U.S., U.K., and Asia that directly mirror BioReliance's geographic and service footprint.
- Toxikon / Scantox: Preclinical and biosafety testing CRO offering extractables/leachables, viral clearance, and analytical services comparable to BioReliance's pre-clinical and release testing portfolio.
- Charles River Laboratories: Global CRO with a dedicated Biologics Testing Solutions division offering biosafety testing, viral clearance, cell bank characterization, and release testing services that directly overlap BioReliance's core offerings.
- SGS Life Sciences: Provides biosafety, viral clearance, cell bank characterization, and GMP release testing for biopharmaceutical manufacturers, with a global lab network directly comparable to BioReliance.
Emerging players
- Pacific BioLabs (PacBio): U.S.-based CRO specializing in biosafety testing, viral clearance, and analytical services for biologics developers, competing with BioReliance primarily in North America.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
BioReliance social profiles
Digital presenceBioReliance financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioReliance leadership team
Management profileNumber of profiles
Profiles1 record
BioReliance funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioReliance M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioReliance
What does BioReliance do?
BioReliance provides contract testing services for biopharmaceutical and biotechnology manufacturers, spanning analytical development, biosafety testing, viral clearance studies, cell and viral bank testing, raw materials testing, and drug substance/product release testing from pre-clinical through licensed production. Services leverage proprietary platforms including the Blazar® molecular detection system and GMP-compliant Next Generation Sequencing (NGS), and are delivered through global facilities in Rockville, Glasgow, Stirling, and Singapore.
Is BioReliance a public or private company?
BioReliance is a private company. It is classified as corporate owned and is currently operating.
When was BioReliance founded?
BioReliance was founded in 1948. It employs 5,001 to 10,000 people.
Where is BioReliance based?
BioReliance is headquartered in Rockville, United States, in the North America region.
How does BioReliance make money?
One revenue line is on record: contract Testing Services.
Who are BioReliance's main competitors?
Broad incumbents on record are Eurofins Scientific, Lonza Group, Catalent and Sartorius. Direct peers are WuXi AppTec (WuXi Biologics), Intertek Pharmaceutical Services, Toxikon / Scantox, Charles River Laboratories and SGS Life Sciences. Pacific BioLabs (PacBio) is listed as an emerging player.
Does BioReliance have an API?
No public API is recorded for BioReliance.
What industry is BioReliance in?
BioReliance's product category is Biopharmaceutical Contract Testing Services. Its primary akta.pro industry code is HLAGAGAF, Analytical Development & QC Testing (Release/Stability/Potency), with a secondary code of HLAGAGAD, Cell Banking & Viral Seed Services (MCB/WCB/VSB). Its NAICS code is 5417 and its SIC code is 8731.